How does venture funding work?

Venture funding (also called venture capital or VC) is when you raise money by selling a piece of your company (equity) to investors who are aiming for a small number of very large winners. It’s not a bank loan: you usually don’t repay cash monthly. Instead, investors get paid if the company has a major “liquidity event” like an acquisition or IPO.

For STEM/medical founders, the key mindset shift is this: VCs aren’t primarily buying your technology. They’re buying a growth trajectory and a credible path to a big outcome, with risk managed by milestones.

The basic mechanics: you sell equity at a valuation

In a venture round, you agree on a valuation (what the company is worth for this deal) and how much cash the investor puts in. The simplest math:

• Post-money valuation = valuation after the new money goes in.
• Pre-money valuation = post-money minus the new money.
• Ownership sold (dilution from the new round) ≈ investment ÷ post-money.

Example: You raise $3M at a $12M post-money valuation. The investor buys ~25% ($3M ÷ $12M). Founders and existing shareholders collectively go from 100% to ~75% (before considering option pools—more on that below).

Most VC rounds are done via a preferred stock class (investors get special rights vs. common stock held by founders/employees). Early-stage rounds sometimes use convertible notes or SAFEs (Simple Agreement for Future Equity), which delay setting a valuation until a later priced round.

Typical funding stages and what investors expect at each

Rounds are labels for a company’s maturity and risk profile. The names vary by geography and sector, but the pattern is consistent: each round “buys down” a specific set of risks.

Pre-seed / Seed

Goal: prove there’s a real problem and a credible wedge into a market. Investors look for early traction (evidence of demand), not perfection. Traction can be revenue, pilots, LOIs (letters of intent), waitlists, or strong usage—depending on your business.

Series A

Goal: prove repeatability. VCs want signs of product-market fit (customers consistently want it and will pay) and a scalable go-to-market motion. “Go-to-market” (GTM) means how you acquire customers: sales, partnerships, self-serve, etc.

Series B/C and beyond

Goal: scale efficiently. The conversation shifts to growth rate, unit economics (profitability per customer), retention, and building a durable advantage.

Not every company needs VC. If your market is smaller, growth is steady (not explosive), or you can fund via revenue, grants, or services, VC may push you into unnatural decisions.

How VCs make money (and why they push for big outcomes)

VC funds have a portfolio model: many investments fail or return little, and a few return most of the fund. That’s why VCs care about venture-scale outcomes—companies that could plausibly become very large.

VCs also operate on a timeline. A typical fund has a limited life, so they prefer companies that can reach a meaningful exit within a reasonable window (exact timing varies). This doesn’t mean they force an exit immediately, but it does shape what they consider “good” opportunities.

Practical implication: if your startup is a “solid business” but not a potential outlier, you may get polite interest but no term sheet. That’s not a judgment on quality—it’s a mismatch with the VC model.

Term sheets: the deal terms that matter most

A term sheet is a non-binding document (mostly) that outlines the key economics and control terms of the investment. Lawyers turn it into final documents. For founders, a few terms drive most outcomes:

• Valuation: impacts dilution now, but don’t optimize for it blindly. A too-high valuation can make the next round harder if you don’t grow into it.
• Liquidation preference: determines who gets paid first in an exit. A common structure is “1x non-participating,” meaning investors get their money back first or convert to common and take their pro-rata share—whichever is better.
• Option pool: shares reserved for future hires. Often the pool is increased before the round, which effectively increases founder dilution. (This is why two deals with the same valuation can dilute founders differently.)
• Board and control: who sits on the board and what decisions require investor approval. The board governs major decisions (CEO hiring/firing, budgets, fundraising, M&A).
• Pro-rata rights: investor’s right to maintain ownership in future rounds by investing more.
• Anti-dilution: protections if you raise a down round (lower valuation later). Details matter; ask counsel to explain the scenario math.

If you’re new to this, treat the term sheet like a system design doc: you’re defining incentives and failure modes. Ask, “What happens if we exit small? If we exit big? If we need more time? If we raise at a lower valuation later?”

The fundraising process: from pitch to money in the bank

Fundraising is a structured sales process. The “product” is your company’s future, and the buyer is the investor. A typical flow:

1. Preparation: define the round size, milestones it funds, and your narrative. Build a pitch deck and a simple financial model (even if early).
2. Investor targeting: pick firms/angels who invest at your stage and in your type of business. “Fit” matters more than prestige.
3. First meetings: you pitch, they probe risks (market size, differentiation, GTM, team).
4. Partner meeting + diligence: deeper review—customer calls, product demo, reference checks, sometimes technical review.
5. Term sheet: you negotiate key terms.
6. Legal close: final documents, signatures, money wired.

Two practical realities surprise first-time founders:

• Momentum matters: investors move faster when they believe others are interested. Running a tight process (meetings clustered) can help.
• “No” is often about timing: many passes are “not now” rather than “never.” Capture feedback, hit milestones, and re-approach.

Common founder pitfalls (especially for technical/medical teams)

1) Raising without a milestone plan

VC money is expensive (dilution + control). You should know exactly what the round achieves: e.g., “12–18 months to reach X customers, Y revenue, or Z regulatory/clinical milestone (varies by sector).” If you can’t articulate the milestone, you can’t justify the round size or valuation.

2) Confusing “cool tech” with a scalable business

Investors will ask: Who pays? How much? How do you reach them? What’s the sales cycle? Who is the economic buyer vs. end user? In healthcare, for example, the user and payer are often different—this changes everything about GTM.

3) Over-optimizing valuation

A higher valuation reduces dilution today but increases the growth you must show to raise the next round. If you miss, you risk a down round, which can be painful for morale and cap table dynamics.

4) Ignoring the cap table and option pool

Your cap table (capitalization table) is the spreadsheet of who owns what. Small changes compound over rounds. Model dilution across 2–3 rounds and include hiring plans (option pool) so you’re not surprised later.

What to do next

1. Model a simple round: pick a raise amount and post-money valuation, then compute dilution and runway. Use /finances to sanity-check assumptions.
2. Write your milestone thesis: one page answering “This round funds X months to achieve Y proof.” Then align hiring and spend to that milestone.
3. Pressure-test your pitch: get a blunt review of your deck and narrative via /roast (or compare versions with /roast-battle).
4. Map your competitive landscape: list direct competitors, substitutes, and “do nothing,” then define your wedge and differentiation using /Competitor_study.